A5101426091- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Mycobacterium research and diagnosis
- Polyomavirus and related diseases
- Lung Cancer Research Studies
- Endoplasmic Reticulum Stress and Disease
- Ferroptosis and cancer prognosis
- Radiation Therapy and Dosimetry
- Fungal Infections and Studies
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Genomics and Diagnostics
- Liver physiology and pathology
- Cancer Mechanisms and Therapy
- Heat shock proteins research
Guangxi Medical University
2017-2025
Background This study aimed to investigate the prognostic value of pretreatment lactate dehydrogenase albumin ratio (LAR) in advanced non-small cell lung cancer (NSCLC) patients treated with first-line programmed death protein 1 (PD-1) checkpoint inhibitors and chemotherapy. Methods A retrospective cohort was conducted on NSCLC PD-1 plus chemotherapy at Guangxi Medical University Cancer Hospital. The receiver operating characteristic (ROC) analysis determined optimal LAR cutoff values for...
The aim of this study was to assessment the efficacy and safety Programmed cell death protein 1 (PD-1)/Programmed death-Ligand (PD-L1) inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 as second later-line treatment for patients advanced non-small lung cancer.In study, pre-treatment clinical laboratory indicators from 73 cancer were retrieved retrospective analysis. According therapy regimes they received, separated into groups, group (PC group), agents'...
The purpose of this study was set to investigate the prognostic role plasmatic levels heat shock protein 90 alpha (HSP90α) at diagnosis in advanced lung cancer patients treated with Programmed cell death 1 (PD-1)/Programmed death-Ligand (PD-L1) inhibitors plus chemotherapy.A total 137 PD-1/PD-L1 chemotherapy admitted Guangxi Medical University Cancer Hospital were enrolled study. Smooth curve fitting conducted address nonlinearity HSP90α and progression-free survival (PFS) overall (OS). We...
Infection is the most common non-cancer cause of death in patients with lung cancer (LC). However, original research reports large sample sizes on epidemiology, pathogen spectrum, immune status changes, and prognosis these are lacking. A retrospective study LC infection was performed at Guangxi Medical University Cancer Hospital from 2014 to 2023. In total, 699 disease complicated by were included study. The incidence increased 4.61% 9.77% 2023 among LC. total 109 types pathogens detected....
<title>Abstract</title> Purpose The currently updated research was conducted in order to determine the effect of TP53 co-mutation on clinical outcomes patients with advanced non-small cell lung cancer who also had EGFR-sensitizing mutation. Methods We used MINORS Methodological items for non-comparative single-arm research, and eligible randomized trials (RCTs), we Cochrane risk bias instrument. Outcomes including progression-free survival (PFS) overall (OS) were extracted further analysis....
Abstract Objective This study aimed to the role of HGF/c-Met signaling pathway in crizotinib-induced apoptosis various lung adenocarcinoma cell lines and xenograft tumor models. Methods In vitro , H2228, H1993, A549 cells were treated with crizotinib. The inhibition proliferation was quantitated by a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Apoptosis quantified flow cytometry. Expression key proteins examined western blotting. vivo H1993 models established....